**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 91221

**Manuscript Type:** EDITORIAL

**2023: A year of accomplishments for the 13 Science Citation Index Expanded- and Emerging Sources Citation Index-indexed *Baishideng* journals**

Wang JL *et al*. 2023: A year of accomplishments for 13 *Baishideng* journals

Jin-Lei Wang, Jia-Ping Yan, Jia-Ru Fan, Xiang Li, Xu Guo, Jia-Wei Li, Yun-Xiaojian Wu, Jing-Jie Wang, Yu-Lu Chen, Li Li, Cong Lin, Xin-Liang Qu, Ji-Hong Liu, Yan-Liang Zhang, Ying-Yi Yuan, Hua-Ge Yu, Yu-Xi Chen, Yi-Xuan Cai, Xiang-Di Zhang, Si Zhao, Zi-Hang Xu, Li Ma, Na Ma, Diao-Mei Guo, Lian-Sheng Ma

**Jin-Lei Wang, Jia-Ping Yan, Jia-Ru Fan, Xiang Li, Xu Guo, Jia-Wei Li, Yun-Xiaojian Wu, Jing-Jie Wang, Yu-Lu Chen, Li Li, Cong Lin, Xin-Liang Qu, Ji-Hong Liu, Yan-Liang Zhang, Ying-Yi Yuan, Hua-Ge Yu, Yu-Xi Chen, Yi-Xuan Cai, Xiang-Di Zhang, Si Zhao, Zi-Hang Xu, Li Ma, Na Ma, Diao-Mei Guo, Lian-Sheng Ma,** Baishideng Publishing Group Inc, Pleasanton, CA 94566, United States

**Author contributions:** Ma LS conceptualized and designed the study; Wang JL organized the study materials, performed the data collection and analysis, and wrote the first draft of the manuscript; All authors reviewed the manuscript, and read and approved the final manuscript.

**Corresponding author: Lian-Sheng Ma, Founder and CEO,** Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, United States. l.s.ma@baishideng.com

**Received:** December 25, 2023

**Revised:** January 2, 2024

**Accepted:** January 2, 2024

**Published online:**

**Abstract**

In 2023, Baishideng Publishing Group (*Baishideng*) routinely published 47 open-access journals, including 46 English-language journals and 1 Chinese-language journal. Our successes were accomplished through the collective dedicated efforts of *Baishideng* staffs, Editorial Board Members, and Peer Reviewers. Among these 47 *Baishideng* journals, 7 are included in the Science Citation Index Expanded (SCIE) and 6 in the Emerging Sources Citation Index (ESCI). With the support of *Baishideng* authors, company staffs, Editorial Board Members, and Peer Reviewers, the publication work of 2023 is about to be successfully completed. This editorial summarizes the 2023 activities and accomplishments of the 13 SCIE- and ESCI-indexed *Baishideng* journals, outlines the *Baishideng* publishing policy changes and additions made this year, and highlights the unique advantages of *Baishideng* journals.

**Key Words:** Baishideng Publishing Group; Journal Impact Factor; Open access; Policy changes; Policy additions; Unique advantages; Anxiety disorders; Colorectal cancer; Inflammatory bowel disease; Hepatocellular carcinoma; Gut microbes; Atrial fibrillation

Wang JL, Yan JP, Fan JR, Li X, Guo X, Li JW, Wu YX, Wang JJ, Chen YL, Li L, Lin C, Qu XL, Liu JH, Zhang YL, Yuan YY, Yu HG, Chen YX, Cai YX, Zhang XD, Zhao S, Xu ZH, Ma L, Ma N, Guo DM, Ma LS. 2023: A year of accomplishments for the 13 Science Citation Index Expanded- and Emerging Sources Citation Index-indexed *Baishideng* journals. *World J Gastroenterol* 2024; In press

**Core Tip:** With the support of Baishideng Publishing Group (*Baishideng*) authors, company staffs, Editorial Board Members, and Peer Reviewers, the publication work of our 47 open-access journals in 2023 is about to be successfully completed. This editorial summarizes the 2023 activities and accomplishments of the 13 *Baishideng* journals indexed in Science Citation Index Expanded and Emerging Sources Citation Index, outlines the *Baishideng* publishing policy changes and additions made this year, and highlights the unique advantages of *Baishideng* journals.

**INTRODUCTION**

In 2023, Baishideng Publishing Group (*Baishideng*) routinely published 47 open-access journals, including 46 English-language journals and 1 Chinese-language journal. Among these, 7 are included in the Science Citation Index Expanded (SCIE) and 6 in the Emerging Sources Citation Index (ESCI). With the support and dedication of all *Baishideng* staffs, Editorial Board Members, and Peer Reviewers, the publication work of these 13 journals in 2023 is about to be successfully completed.

**BRIEF SUMMARY FOR THE 13 SCIE- AND ESCI-INDEXED *BAISHIDENG* JOURNALS IN 2023**

***Number of manuscripts received and published***

As of December 20, 2023, the 13 SCIE- and ESCI-indexed *Baishideng* journals received a total of 5726 manuscript submissions, of which 2533 (44.2%) passed peer review and were published online (Figure 1). Among those, the *World Journal of Gastroenterology* received 1602 manuscript submissions and published 428 articles, with 827 (51.6%) having been rejected and 360 (22.5%) still under peer review.

The 2533 articles published in the collective *Baishideng* journals have already garnered a total of 1330 citations, accounted for by 681 (26.9%) of those articles. An outstanding accomplishment has been achieved by 45 (1.8%) of those articles having received more than 5 citations each and 10 (0.4%)[1-10] having been cited more than 10 times in the current year (Table 1).

***Summary of the manuscript peer reviews***

As of December 20, 2023, the 13 SCIE- and ESCI-indexed *Baishideng* journals received a total of 10394 peer review reports from Editorial Board MembersandPeer Reviewers, accounting for an average of 1.82 (10394/5726) peer review reports per manuscript. Declines to conduct peer review of manuscripts numbered 36644.

***Manuscript invitations***

As of December 20, 2023, the 13 SCIE- and ESCI-indexed *Baishideng* journals received a total of 1859 title submissions for invited manuscripts, of which 1597 (85.9%) titles were accepted. Among the 1597 accepted invited manuscript titles, 678 manuscripts have been submitted successfully and 133 articles have been published online. For the remainder, the invited manuscripts have already been rejected or have not yet been submitted.

***Journal Impact Factor™***

According to the *Journal Citation Reports*™ released on June 28, 2023, all of the 13 SCIE- and ESCI-indexed *Baishideng* journals received updated Journal Impact Factors™ (JIFs).

**The 7 SCIE-indexed journals:** (1) *World Journal of Gastroenterology*, JIF: 4.3; (2) *World Journal of Diabetes*, JIF: 4.2; (3) *World Journal of Stem Cells*, JIF: 4.1; (4) *World Journal of Psychiatry*, JIF: 3.1; (5) *World Journal of Gastrointestinal Oncology*, JIF: 3.0; (6) *World Journal of Gastrointestinal Surgery*, JIF: 2.0; and (7) *World Journal of Clinical Cases*, JIF: 1.1.

**The 6 ESCI-indexed journals:** (1) *World Journal of Clinical Oncology*, JIF: 2.8; (2) *World Journal of Radiology*, JIF: 2.5; (3) *World Journal of Hepatology*, JIF: 2.4; (4) *World Journal of Gastrointestinal Endoscopy*, JIF: 2.0; (5) *World Journal of Cardiology*, JIF: 1.9; and (5) *World Journal of Orthopedics*, JIF: 1.9.

**POLICY CHANGES AND POLICY ADDITIONS RELATED TO *BAISHIDENG* JOURNALS IN 2023**

***Publishing partners***

In 2023, well-known institutions in China were carefully chosen for invitation to become publishing partners for *Baishideng* journals, six of which successfully completed the joint vetting process and formally partnered with five *Baishideng* journals. These respected institutions include Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute of Fudan University, and Biliary Tract Disease Institute of Fudan University partnering with *World Journal of Gastroenterology*. Each of these six new publishing partners will help *Baishideng* to better promote the development of *Baishideng* journals, while *Baishideng* will help these publishing partners to enhance their international academic cooperation and exchange activities, strengthening their academic reputations nationally and extending them worldwide.

***Manuscript initial submission***

Starting in August 2023, the process of initial submission was updated so that authors can conveniently make the first upload of their manuscript without restrictions on writing style, file format, or need for accompanying relevant documents. This enables authors to submit their manuscripts faster, ultimately attracting more authors to submit their manuscripts to *Baishideng* journals. The updated guidelines for authors can be found at <https://www.wjgnet.com/bpg/gerinfo/204>.

***Co-authors policy***

To acknowledge the evolution of research towards equal contributions among broader groups of researchers, in August 2023 *Baishideng* initiated allowance of co-first authorship and co-corresponding authorship. Co-first authors and co-corresponding authors are now formally cited in a footnote for manuscripts published in *Baishideng* journals. The detailed co-authorship policy can be found at: <https://www.wjgnet.com/bpg/GerInfo/310>.

***Article Processing Charge policy***

To better acknowledge the contributions by Editorial Board Members and Peer Reviewers, and to help authors from low- and middle-income countries, in December 2023 *Baishideng* updated its Article Processing Charge (APC) policy. If an unsolicited manuscript has a corresponding author who is a member of the Editorial Board or serves as a Peer Reviewer for *Baishideng* journals, the APC will be reduced by 50% (previously 10%), and *Baishideng* will provide discounts in line with the Research4Life Programme (<https://www.research4life.org/access/eligibility/>) as follows: Group A countries will receive full waiver of the APC; and Group B countries will receive a 50% discount. For the detailed policy of APC, please visit: <https://www.wjgnet.com/bpg/gerinfo/242>.

***Reference Citation Analysis***

Starting in April 2023, *Reference Citation Analysis* (*RCA*), a unique artificial intelligence system for citation index evaluation of literature, sharpened its focus onto the medical sciences and life sciences literature. As of December 20, 2023, a total of 54375058 articles and 6129 quality journals encompassing 124 categories are indexed in *RCA.* Meanwhile, 4039 scholars from countries across the globe registered as *RCA* scholars, and 48981 subscribers subscribed to *RCA*. For more information about *RCA*, please visit: <https://www.referencecitationanalysis.com/>.

**UNIQUE ADVANTAGES OF *BAISHIDENG* JOURNALS**

***Manuscript publication processing time***

In general, for most of the manuscripts submitted to any *Baishideng* journal, the first decision/peer review procedure can be done within 28 d from the date that the journal receives the manuscript; other than this, the maximum time will not exceed 90 d. Moreover, most accepted papers can be published online within 20 d; other than this, the maximum time will not exceed 30 d.

***Control of academic quality***

To control the academic quality of *Baishideng* journals’ manuscripts, all Editorial Board Members are invited to participate in the second decision process. In addition, all Editorial Board Members are invited to write editorials on accepted articles that are ready to be published, to expand their academic impact.

***Control of language quality***

To control the language quality of *Baishideng* journals’ published articles, from January to November 2023, more than 760 manuscripts were edited by our language Editors, and *Baishideng* paid nearly $40000 for this.

***Fight against plagiarism***

To fight against plagiarism and to ensure high ethical standards for all of the published articles, *Baishideng* joined iThenticate (CrossCheck) in 2014. iThenticate is an effective tool for detecting unoriginal content, enabling our editors to preserve our journals’ integrity and authors' copyright. For all accepted manuscripts, we will conduct iThenticate detection. If a significant amount of overlapping text (*e.g.*, overlap > 5% or similarity > 50%) is found, we will immediately verify if the manuscript is associated with plagiarism. Once plagiarism is confirmed, the manuscript will be rejected immediately and all authors of the manuscript will be included in the black-list of *Baishideng* journals.

***Ethical requirements***

For all manuscripts involving animal/human experiments, author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee. The approved ethics document(s) will be released online, together with the manuscript. This is why none of the articles published in *Baishideng* journals were retracted due to academic misconduct in 2022-2023. This practice not only effectively improves the reliability of articles published in *Baishideng* journals but also helps to eliminate articles from “Fake-Paper Factories”.

***Authors/Editorial Board Members' evaluation and Readers' comments***

After an article is published in any *Baishideng* journal, the authors are invited to evaluate their experience with the article publishing process, the Editorial Board Members are invited to further track and evaluate the scientific and linguistic quality of the article, and the readers in the relevant field are invited to comment on the article. As of December 20, 2023, a total of 2409 authors’ evaluations and 1999 Editorial Board Members’ evaluations have been received by the *Baishideng* journals for the year. From September to December 2023, a total of 78 readers’ comments have been received by the *Baishideng* journals.

**CONCLUSION**

Finally, we hope that more researchers/authors will continue to submit high-quality manuscripts to *Baishideng* journals in 2024, and all Editorial Board Members/Peer Reviewers will continue to conduct high-quality peer review for *Baishideng* journals in 2024, and support *Baishideng* to publish more high-quality articles that will make substantive contributions to the development of clinical and basic medical research.

**REFERENCES**

1 **Liu XQ**, Guo YX, Xu Y. Risk factors and digital interventions for anxiety disorders in college students: Stakeholder perspectives. *World J Clin Cases* 2023; **11**: 1442-1457 [PMID: 36926387 DOI: 10.12998/wjcc.v11.i7.1442]

2 **Saraiva MR**, Rosa I, Claro I. Early-onset colorectal cancer: A review of current knowledge. *World J Gastroenterol* 2023; **29**: 1289-1303 [PMID: 36925459 DOI: 10.3748/wjg.v29.i8.1289]

3 **Roy S**, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; **29**: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]

4 **Nevola R**, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, Imbriani S, Claar E, Cozzolino D, Sasso FC, Marrone A, Adinolfi LE, Rinaldi L. Predictors of early and late hepatocellular carcinoma recurrence. *World J Gastroenterol* 2023; **29**: 1243-1260 [PMID: 36925456 DOI: 10.3748/wjg.v29.i8.1243]

5 **Colella M**, Charitos IA, Ballini A, Cafiero C, Topi S, Palmirotta R, Santacroce L. Microbiota revolution: How gut microbes regulate our lives. *World J Gastroenterol* 2023; **29**: 4368-4383 [PMID: 37576701 DOI: 10.3748/wjg.v29.i28.4368]

6 **Batta A**, Hatwal J, Batta A, Verma S, Sharma YP. Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship. *World J Cardiol* 2023; **15**: 229-243 [PMID: 37274376 DOI: 10.4330/wjc.v15.i5.229]

7 **Dludla PV**, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, Basson AK, Pheiffer C, Kengne AP. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. *World J Diabetes* 2023; **14**: 130-146 [PMID: 37035220 DOI: 10.4239/wjd.v14.i3.130]

8 **Ganguly R**, Singh SV, Jaiswal K, Kumar R, Pandey AK. Modulatory effect of caffeic acid in alleviating diabetes and associated complications. *World J Diabetes* 2023; **14**: 62-75 [PMID: 36926656 DOI: 10.4239/wjd.v14.i2.62]

9 **Dolinger MT**, Kayal M. Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making. *World J Gastroenterol* 2023; **29**: 2272-2282 [PMID: 37124889 DOI: 10.3748/wjg.v29.i15.2272]

10 **Muthu S**, Patil SC, Jeyaraman N, Jeyaraman M, Gangadaran P, Rajendran RL, Oh EJ, Khanna M, Chung HY, Ahn BC. Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: A meta-analysis. *World J Orthop* 2023; **14**: 23-41 [PMID: 36686284 DOI: 10.5312/wjo.v14.i1.23]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict-of-interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 25, 2023

**First decision:** December 27, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ferraioli G, Italy **S-Editor:** Qu XL **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Rate of publication with respect to the total number of submissions for the 13 *Baishideng* journals indexed in Science Citation Index Expanded and Emerging Sources Citation Index.**

**Table 1 Articles published in 2023 in the 13 *Baishideng* journals indexed in Science Citation Index Expanded and Emerging Sources Citation Index cited more than 5 times in the current year**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **No.** | **DOI** | **Article title** | **Journal title** | **Volume and issue** | **Article type** | **Times cited** | **Total article views** | **PDF downloads** |
| 1 | 10.12998/wjcc.v11.i7.1442 | Risk factors and digital interventions for anxiety disorders in college students: Stakeholder perspectives | *World Journal of Clinical Cases* | Volume 11 issue 7 | Review | 22 | 2747 | 161 |
| 2 | 10.3748/wjg.v29.i8.1289 | Early-onset colorectal cancer: A review of current knowledge | *World Journal of Gastroenterology* | Volume 29 issue 8 | Review | 20 | 4085 | 284 |
| 3 | 10.3748/wjg.v29.i14.2078 | Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives | *World Journal of Gastroenterology* | Volume 29 issue 14 | Review | 16 | 4810 | 331 |
| 4 | 10.3748/wjg.v29.i8.1243 | Predictors of early and late hepatocellular carcinoma recurrence | *World Journal of Gastroenterology* | Volume 29 issue 8 | Review | 12 | 3549 | 212 |
| 5 | 10.3748/wjg.v29.i28.4368 | Microbiota revolution: How gut microbes regulate our lives | *World Journal of Gastroenterology* | Volume 29 issue 28 | Review | 11 | 2921 | 85 |
| 6 | 10.4330/wjc.v15.i5.229 | Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship | *World Journal of Cardiology* | Volume 15 issue 5 | Minireviews | 10 | 2173 | 316 |
| 7 | 10.4239/wjd.v14.i3.130 | Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress | *World Journal of Diabetes* | Volume 14 issue 3 | Review | 10 | 3130 | 214 |
| 8 | 10.4239/wjd.v14.i2.62 | Modulatory effect of caffeic acid in alleviating diabetes and associated complications | *World Journal of Diabetes* | Volume 14 issue 2 | Review | 10 | 3041 | 205 |
| 9 | 10.3748/wjg.v29.i15.2272 | Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making | *World Journal of Gastroenterology* | Volume 29 issue 15 | Minireviews | 10 | 4090 | 197 |
| 10 | 10.5312/wjo.v14.i1.23 | Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: A meta-analysis | *World Journal of Orthopedics* | Volume 14 issue 1 | Meta-Analysis | 10 | 2904 | 176 |
| 11 | 10.3748/wjg.v29.i7.1157 | Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets | *World Journal of Gastroenterology* | Volume 29 issue 7 | Review | 9 | 3717 | 245 |
| 12 | 10.3748/wjg.v29.i2.257 | COVID-19 and liver injury: An ongoing challenge | *World Journal of Gastroenterology* | Volume 29 issue 2 | Review | 9 | 3376 | 233 |
| 13 | 10.3748/wjg.v29.i1.19 | Microbiota of the gastrointestinal tract: Friend or foe? | *World Journal of Gastroenterology* | Volume 29 issue 1 | Review | 9 | 3087 | 233 |
| 14 | 10.4254/wjh.v15.i2.180 | Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy | *World Journal of Hepatology* | Volume 15 issue 2 | Review | 9 | 2654 | 193 |
| 15 | 10.3748/wjg.v29.i6.1054 | Immunotherapy for hepatocellular carcinoma: Current status and future perspectives | *World Journal of Gastroenterology* | Volume 29 issue 6 | Minireviews | 8 | 3693 | 274 |
| 16 | 10.3748/wjg.v29.i16.2452 | Updates on global epidemiology, risk and prognostic factors of gastric cancer | *World Journal of Gastroenterology* | Volume 29 issue 16 | Review | 8 | 3249 | 172 |
| 17 | 10.3748/wjg.v29.i1.126 | Management of metabolic-associated fatty liver disease: The diabetology perspective | *World Journal of Gastroenterology* | Volume 29 issue 1 | Minireviews | 8 | 3798 | 251 |
| 18 | 10.4253/wjge.v15.i3.133 | Quality of bowel preparation in patients with inflammatory bowel disease undergoing colonoscopy: What factors to consider? | *World Journal of Gastrointestinal Endoscopy* | Volume 15 issue 3 | Minireviews | 8 | 2057 | 136 |
| 19 | 10.12998/wjcc.v11.i3.493 | Non-pulmonary involvement in COVID-19: A systemic disease rather than a pure respiratory infection | *World Journal of Clinical Cases* | Volume 11 issue 3 | Minireviews | 7 | 2018 | 137 |
| 20 | 10.5306/wjco.v14.i4.138 | Immunotherapy in glioblastoma treatment: Current state and future prospects | *World Journal of Clinical Oncology* | Volume 14 issue 4 | Review | 7 | 2342 | 149 |
| 21 | 10.4254/wjh.v15.i1.1 | Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise | *World Journal of Hepatology* | Volume 15 issue 1 | Review | 7 | 3437 | 292 |
| 22 | 10.5498/wjp.v13.i7.409 | Delivering substance use prevention interventions for adolescents in educational settings: A scoping review | *World Journal of Psychiatry* | Volume 13 issue 7 | Minireviews | 7 | 2155 | 41 |
| 23 | 10.4330/wjc.v15.i1.13 | Role of fibrinogen, albumin and fibrinogen to albumin ratio in determining angiographic severity and outcomes in acute coronary syndrome | *World Journal of Cardiology* | Volume 15 issue 1 | Observational Study | 6 | 2197 | 132 |
| 24 | 10.12998/wjcc.v11.i2.464 | X-linked Charcot-Marie-Tooth disease after SARS-CoV-2 vaccination mimicked stroke-like episodes: A case report | *World Journal of Clinical Cases* | Volume 11 issue 2 | Case Report | 6 | 2019 | 143 |
| 25 | 10.3748/wjg.v29.i9.1395 | Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond | *World Journal of Gastroenterology* | Volume 29 issue 9 | Review | 6 | 3344 | 209 |
| 26 | 10.3748/wjg.v29.i4.682 | Gaseous metabolites as therapeutic targets in ulcerative colitis | *World Journal of Gastroenterology* | Volume 29 issue 4 | Minireviews | 6 | 3116 | 169 |
| 27 | 10.3748/wjg.v29.i11.1685 | Factors affecting the quality of bowel preparation for colonoscopy in hard-to-prepare patients: Evidence from the literature | *World Journal of Gastroenterology* | Volume 29 issue 11 | Review | 6 | 4841 | 272 |
| 28 | 10.5306/wjco.v14.i3.99 | Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature | *World Journal of Clinical Oncology* | Volume 14 issue 3 | Review | 5 | 3426 | 208 |
| 29 | 10.4239/wjd.v14.i5.512 | Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment | *World Journal of Diabetes* | Volume 14 issue 5 | Review | 5 | 1753 | 91 |
| 30 | 10.4239/wjd.v14.i4.396 | Management of diabesity: Current concepts | *World Journal of Diabetes* | Volume 14 issue 4 | Review | 5 | 3501 | 255 |
| 31 | 10.4239/wjd.v14.i1.35 | Future applications of exosomes delivering resolvins and cytokines in facilitating diabetic foot ulcer healing | *World Journal of Diabetes* | Volume 14 issue 1 | Minireviews | 5 | 2783 | 210 |
| 32 | 10.4239/wjd.v14.i1.48 | Gut region-specific TNFR expression: TNFR2 is more affected than TNFR1 in duodenal myenteric ganglia of diabetic rats | *World Journal of Diabetes* | Volume 14 issue 1 | Basic Study | 5 | 2463 | 159 |
| 33 | 10.3748/wjg.v29.i7.1173 | Choosing the best endoscopic approach for post-bariatric surgical leaks and fistulas: Basic principles and recommendations | *World Journal of Gastroenterology* | Volume 29 issue 7 | Minireviews | 5 | 2591 | 164 |
| 34 | 10.3748/wjg.v29.i7.1202 | Comparison of genomic and transcriptional microbiome analysis in gastric cancer patients and healthy individuals | *World Journal of Gastroenterology* | Volume 29 issue 7 | Case Control Study | 5 | 3386 | 118 |
| 35 | 10.3748/wjg.v29.i6.908 | COVID-19 and liver injury in individuals with obesity | *World Journal of Gastroenterology* | Volume 29 issue 6 | Opinion Review | 5 | 2809 | 170 |
| 36 | 10.3748/wjg.v29.i3.508 | Artificial intelligence and inflammatory bowel disease: Where are we going? | *World Journal of Gastroenterology* | Volume 29 issue 3 | Minireviews | 5 | 3950 | 337 |
| 37 | 10.3748/wjg.v29.i21.3241 | Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review | *World Journal of Gastroenterology* | Volume 29 issue 21 | Review | 5 | 2715 | 123 |
| 38 | 10.3748/wjg.v29.i2.241 | Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments | *World Journal of Gastroenterology* | Volume 29 issue 2 | Review | 5 | 2799 | 220 |
| 39 | 10.3748/wjg.v29.i2.272 | Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology | *World Journal of Gastroenterology* | Volume 29 issue 2 | Review | 5 | 2850 | 216 |
| 40 | 10.3748/wjg.v29.i18.2733 | Study of tumor necrosis factor receptor in the inflammatory bowel disease | *World Journal of Gastroenterology* | Volume 29 issue 18 | Review | 5 | 2084 | 121 |
| 41 | 10.3748/wjg.v29.i1.157 | Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies | *World Journal of Gastroenterology* | Volume 29 issue 1 | Minireviews | 5 | 2091 | 198 |
| 42 | 10.3748/wjg.v29.i1.43 | Current status and future perspectives of radiomics in hepatocellular carcinoma | *World Journal of Gastroenterology* | Volume 29 issue 1 | Review | 5 | 3733 | 251 |
| 43 | 10.4251/wjgo.v15.i2.251 | Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? | *World Journal of Gastrointestinal Oncology* | Volume 15 issue 2 | Review | 5 | 2595 | 189 |
| 44 | 10.4251/wjgo.v15.i1.128 | Risk factors, prognostic predictors, and nomograms for pancreatic cancer patients with initially diagnosed synchronous liver metastasis | *World Journal of Gastrointestinal Oncology* | Volume 15 issue 1 | Retrospective Study | 5 | 2172 | 95 |
| 45 | 10.4240/wjgs.v15.i4.495 | Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review | *World Journal of Gastrointestinal Surgery* | Volume 15 issue 4 | Review | 5 | 2685 | 126 |

Among these 45 articles, 24 (53.3%) were published in *World Journal of Gastroenterology*, 6 (13.3%) were published in *World Journal of Diabetes*, 3 (6.7%) were published in *World Journal of Clinical Cases,* and 12 (26.7%) were published in another 8 journals.